title: Tapentadol PR for Pain Syndromes in Real Life Patients with Hematological Malignancy.
abstract: BACKGROUND
  More than 50% of oncohematological patients suffer from pain syndrome, mostly originating from the bone, which often include nociceptive and neuropathic complaints. Tapentadol, a recently available treatment option for cancer pain, exerts a dual analgesic mechanisms (opioid and noradrenergic), allowing for a high clinical efficacy as well as for a reduction in adverse events compared to traditional opioids.
  
  
  OBJECTIVE
  To explore the safety and efficacy of tapentadol as a suitable agent for the pain management in the setting of oncohematology.
  
  
  METHODS
  Our observational study included 36 patients with basal pain intensity (NRS) ranging from 5 to 10. Tapentadol prolonged release (PR) was given at the initial dose of 50 mg BID and careful titrated according to the achieved pain control.
  
  
  RESULTS
  Tapentadol PR was given at the dosages ranging from 200 and 260 mg/day after a careful titration, allowed for a clinically (-7 points NRS) remarkable reduction of pain intensity without any significant side effects.
  
  
  CONCLUSIONS
  In oncohematological patients on pain, tapentadol PR was effective and well tolerated, so representing a suitable treatment option in this difficult setting.
authors.affiliation: Department of Cellular Biotechnology and Hematology, University La Sapienza of Rome, Italy. brunetti@bce.uniroma1.it.
authors.forename: Gregorio A
authors.initials: GA
authors.lastname: Brunetti
authors.forename: Giovanna
authors.initials: G
authors.lastname: Palumbo
authors.forename: Giacomo S
authors.initials: GS
authors.lastname: Morano
authors.forename: Erminia
authors.initials: E
authors.lastname: Baldacci
authors.forename: Ida
authors.initials: I
authors.lastname: Carmosino
authors.forename: Giorgia
authors.initials: G
authors.lastname: Annechini
authors.forename: Romina
authors.initials: R
authors.lastname: Talone
authors.forename: Sara
authors.initials: S
authors.lastname: Kiflom
authors.forename: Giada
authors.initials: G
authors.lastname: Mastrogiacomo
authors.forename: Sara
authors.initials: S
authors.lastname: Grammatico
authors.forename: Marta
authors.initials: M
authors.lastname: Chisini
authors.forename: Adriana
authors.initials: A
authors.lastname: Costa
authors.forename: Andrea
authors.initials: A
authors.lastname: Tendas
authors.forename: Laura
authors.initials: L
authors.lastname: Scaramucci
authors.forename: Marco
authors.initials: M
authors.lastname: Giovannini
authors.forename: Pasquale
authors.initials: P
authors.lastname: Niscola
authors.forename: Maria T
authors.initials: MT
authors.lastname: Petrucci
authors.forename: Claudio
authors.initials: C
authors.lastname: Cartoni
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000150:complications* / Q000188:drug therapy*; D059408:Pain Management / Q000379:methods; D010636:Phenols / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D000077432:Tapentadol
chemical_list: D000701:Analgesics, Opioid; D010636:Phenols; D000077432:Tapentadol